Table 3.
Bivariate analysis on predictors of clinical remission after immunomodulator introduction.
| Bivariate analysis | ||
|---|---|---|
| HR [95% CI] | p-Value | |
| Gender [male] | 0.87 [0.45;1.68] | 0.690 |
| Active smoker | 1.31 [0.62;2.77] | 0.479 |
| Disease locationa | ||
| Ileum: L1 | 1 | |
| Colon: L2 | 1.55 [0.61;3.95] | 0.359 |
| Ileocolonic: L3 | 0.88 [0.39;1.96] | 0.758 |
| Behavioura,b | ||
| Uncomplicated [B1] | 1 | |
| Complicated [B2 + B3] | 1.21 [0.59;2.48] | 0.593 |
| Age at diagnosis [years]a | ||
| < 16 | 1 | |
| 17–40 | 1.07 [0.43;2.63] | 0.890 |
| > 40 | 1.25 [0.41;3.79] | 0.689 |
| Perianal disease | 1.19 [0.61;2.34] | 0.601 |
| Previous intestinal resection | 0.90 [0.45;1.80] | 0.764 |
| 2nd/3rd/4th line of anti-TNF therapy vs 1st line α | 1.67 [0.83;3.30] | 0.148 |
| Anti-TNF type [IFX vs ADA] α | 0.60 [0.29;1.26] | 0.178 |
| Concomitant treatment | ||
| Oral 5-ASA | 1.39 [0.61;3.22] | 0.413 |
| Budesonide | 1.18 [0.48;2.88] | 0.714 |
| Systemic [oral or intravenous] | 1.53 [0.76;30.7] | 0.234 |
| Steroids | 1.54 [0.79;2.97] | 0.205 |
| IMM type [methotrexate vs azathioprine] | 1.94 [0.96;3.92] | 0.065 |
| Time between anti-TNF therapy and IMM introduction < 12 months vs > = 12 months | 1.11 [0.56;2.34] | 0.756 |
5-ASA, 5-aminosalicylic acid; IFX, infliximab; ADA, adalimumab; IMM, immunomodulatory; TNF, tumour necrosis factor; HR, hazard ratio; CI, confidence interval.
HR, hazard ratio. 95% CI, 95% confidence interval
aAccording to the Montreal classification.
bFactors included in multivariate analysis.